Please enable JavaScript to continue using this application.

Compare $CHRS vs $ORGO | Chartloom

Compare

$CHRS vs $ORGO

Coherus Oncology Inc · Organogenesis Holdings Inc

CHRS

Coherus Oncology Inc

ORGO

Organogenesis Holdings Inc

Compare $CHRS vs $ORGO

Comparing Coherus Oncology Inc and Organogenesis Holdings Inc

CHRSCoherus Oncology Inc

ORGOOrganogenesis Holdings Inc

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

ORGOOrganogenesis Holdings Inc

Market cap

$166M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.74x

Rev growth (TTM)

6.5%

YTD performance

-72.2%

52W performance

-68.8%

FCF yield

12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

ORGO

Detailed metrics comparison

CHRS

Coherus Oncology Inc

ORGO

Organogenesis Holdings Inc

Market Cap

CHRS$165M

ORGO$166M

Enterprise Value

CHRS$134M

ORGO$132M

Price

CHRS$1.07

ORGO$1.29

P/E Ratio

CHRSN/A

ORGON/A

P/S Ratio

CHRS3.24x

ORGO0.36x

EV/Sales

CHRS2.63x

ORGO0.29x

EV/EBITDA

CHRS2.57x

ORGO7.37x

P/B Ratio

CHRS2.95x

ORGO0.59x

P/FCF Ratio

CHRSN/A

ORGO7.96x

EV/FCF

CHRS-0.72x

ORGO6.31x

PEG Ratio

CHRSN/A

ORGON/A

Forward P/E (NTM)

CHRSN/A

ORGON/A

Forward P/S (NTM)

CHRS2.04x

ORGO0.74x

Revenue (TTM)

CHRS$51M

ORGO$457M

Revenue Growth (YoY)

CHRS-64.3%

ORGO6.5%

Forward Rev Growth

CHRS67.8%

ORGO37.6%

Gross Margin (TTM)

CHRS68.9%

ORGO70.4%

Operating Margin (TTM)

CHRS0.0%

ORGO0.0%

EBITDA Margin (TTM)

CHRS-288.0%

ORGO-2.0%

Net Margin (TTM)

CHRS-259.4%

ORGO-23.1%

FCF Margin (TTM)

CHRS-365.2%

ORGO4.6%

Net Income (TTM)

CHRS$-132M

ORGO$-106M

FCF (TTM)

CHRS$-186M

ORGO$21M

EPS (TTM)

CHRS-$0.85

ORGO-$0.82

ROE (TTM)

CHRS-18336.0%

ORGO-2260.0%

ROA (TTM)

CHRS-4290.0%

ORGO-1654.0%

ROIC (TTM)

CHRS-10716.0%

ORGO-2187.0%

Cash

CHRS$83M

ORGO$46M

Debt

CHRS$52M

ORGO$12M

Net Cash/Debt

CHRS$31M

ORGO$34M

Current Ratio (TTM)

CHRS1.77x

ORGO3.52x

Quick Ratio (TTM)

CHRS1.58x

ORGO2.66x

Debt/Equity (TTM)

CHRS0.85x

ORGO0.04x

Debt/Assets (TTM)

CHRS0.0%

ORGO0.0%

Interest Coverage (TTM)

CHRSN/A

ORGON/A

Net Debt/EBITDA (TTM)

CHRS0.00x

ORGO0.00x

Beta

CHRS0.99

ORGO1.44

52W Performance

CHRS-39.2%

ORGO-68.8%

YTD Performance

CHRS-21.9%

ORGO-72.2%

% from 52W High

CHRS-59.1%

ORGO-81.8%

% from 52W Low

CHRS9.9%

ORGO3.2%

Asset Turnover (TTM)

CHRS0.17x

ORGO0.90x

FCF Yield (TTM)

CHRS-112.7%

ORGO12.6%

Earnings Yield (TTM)

CHRS-80.1%

ORGO-63.8%

Dividend Yield (TTM)

CHRSN/A

ORGON/A

Rule of 40

CHRS-429.5

ORGO11.1

EV/GP/RG

CHRS0.05

ORGO0.01

Ticker research

View CHRS research View ORGO research

Metric	CHRS Coherus Oncology Inc	ORGO Organogenesis Holdings Inc
Market & Valuation
Market Cap	$165M	$166M
Enterprise Value	$134M	$132M
Price	$1.07	$1.29
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.36x
EV/Sales	2.63x	0.29x
EV/EBITDA	2.57x	7.37x
P/B Ratio	2.95x	0.59x
P/FCF Ratio	N/A	7.96x
EV/FCF	-0.72x	6.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	0.74x
Revenue & Growth
Revenue (TTM)	$51M	$457M
Revenue Growth (YoY)	-64.3%	6.5%
Forward Rev Growth	67.8%	37.6%
Profitability
Gross Margin (TTM)	68.9%	70.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	-2.0%
Net Margin (TTM)	-259.4%	-23.1%
FCF Margin (TTM)	-365.2%	4.6%
Net Income (TTM)	$-132M	$-106M
FCF (TTM)	$-186M	$21M
EPS (TTM)	-$0.85	-$0.82
ROE (TTM)	-18336.0%	-2260.0%
ROA (TTM)	-4290.0%	-1654.0%
ROIC (TTM)	-10716.0%	-2187.0%
Financial Health
Cash	$83M	$46M
Debt	$52M	$12M
Net Cash/Debt	$31M	$34M
Current Ratio (TTM)	1.77x	3.52x
Quick Ratio (TTM)	1.58x	2.66x
Debt/Equity (TTM)	0.85x	0.04x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.44
52W Performance	-39.2%	-68.8%
YTD Performance	-21.9%	-72.2%
% from 52W High	-59.1%	-81.8%
% from 52W Low	9.9%	3.2%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.90x
FCF Yield (TTM)	-112.7%	12.6%
Earnings Yield (TTM)	-80.1%	-63.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	11.1
EV/GP/RG	0.05	0.01
Ticker research	View CHRS research	View ORGO research

Valuation

P/S Ratio

ORGO

0.36x

CHRS

3.24x

EV/FCF

CHRS

-0.72x

ORGO

6.31x

Growth & revenue

Revenue Growth TTM

ORGO

6.5%

CHRS

-64.3%

Forward Revenue Growth

CHRS

67.8%

ORGO

37.6%

Profitability & performance

Gross Margin

ORGO

70.4%

CHRS

68.9%

ROE

ORGO

-2260.0%

CHRS

-18336.0%

FCF Yield %

ORGO

12.6%

CHRS

-112.7%

52-Week Performance

CHRS

-39.2%

ORGO

-68.8%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

ORGO

Organogenesis Holdings Inc

Market Cap

CHRS$165M

ORGO$166M

Enterprise Value

CHRS$134M

ORGO$132M

Price

CHRS$1.07

ORGO$1.29

P/E Ratio

CHRSN/A

ORGON/A

P/S Ratio

CHRS3.24x

ORGO0.36x

EV/Sales

CHRS2.63x

ORGO0.29x

EV/EBITDA

CHRS2.57x

ORGO7.37x

P/B Ratio

CHRS2.95x

ORGO0.59x

P/FCF Ratio

CHRSN/A

ORGO7.96x

EV/FCF

CHRS-0.72x

ORGO6.31x

PEG Ratio

CHRSN/A

ORGON/A

Forward P/E (NTM)

CHRSN/A

ORGON/A

Forward P/S (NTM)

CHRS2.04x

ORGO0.74x

Revenue (TTM)

CHRS$51M

ORGO$457M

Revenue Growth (YoY)

CHRS-64.3%

ORGO6.5%

Forward Rev Growth

CHRS67.8%

ORGO37.6%

Gross Margin (TTM)

CHRS68.9%

ORGO70.4%

Operating Margin (TTM)

CHRS0.0%

ORGO0.0%

EBITDA Margin (TTM)

CHRS-288.0%

ORGO-2.0%

Net Margin (TTM)

CHRS-259.4%

ORGO-23.1%

FCF Margin (TTM)

CHRS-365.2%

ORGO4.6%

Net Income (TTM)

CHRS$-132M

ORGO$-106M

FCF (TTM)

CHRS$-186M

ORGO$21M

EPS (TTM)

CHRS-$0.85

ORGO-$0.82

ROE (TTM)

CHRS-18336.0%

ORGO-2260.0%

ROA (TTM)

CHRS-4290.0%

ORGO-1654.0%

ROIC (TTM)

CHRS-10716.0%

ORGO-2187.0%

Cash

CHRS$83M

ORGO$46M

Debt

CHRS$52M

ORGO$12M

Net Cash/Debt

CHRS$31M

ORGO$34M

Current Ratio (TTM)

CHRS1.77x

ORGO3.52x

Quick Ratio (TTM)

CHRS1.58x

ORGO2.66x

Debt/Equity (TTM)

CHRS0.85x

ORGO0.04x

Debt/Assets (TTM)

CHRS0.0%

ORGO0.0%

Interest Coverage (TTM)

CHRSN/A

ORGON/A

Net Debt/EBITDA (TTM)

CHRS0.00x

ORGO0.00x

Beta

CHRS0.99

ORGO1.44

52W Performance

CHRS-39.2%

ORGO-68.8%

YTD Performance

CHRS-21.9%

ORGO-72.2%

% from 52W High

CHRS-59.1%

ORGO-81.8%

% from 52W Low

CHRS9.9%

ORGO3.2%

Asset Turnover (TTM)

CHRS0.17x

ORGO0.90x

FCF Yield (TTM)

CHRS-112.7%

ORGO12.6%

Earnings Yield (TTM)

CHRS-80.1%

ORGO-63.8%

Dividend Yield (TTM)

CHRSN/A

ORGON/A

Rule of 40

CHRS-429.5

ORGO11.1

EV/GP/RG

CHRS0.05

ORGO0.01

Ticker research

View CHRS research View ORGO research

Metric	CHRS Coherus Oncology Inc	ORGO Organogenesis Holdings Inc
Market & Valuation
Market Cap	$165M	$166M
Enterprise Value	$134M	$132M
Price	$1.07	$1.29
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.36x
EV/Sales	2.63x	0.29x
EV/EBITDA	2.57x	7.37x
P/B Ratio	2.95x	0.59x
P/FCF Ratio	N/A	7.96x
EV/FCF	-0.72x	6.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	0.74x
Revenue & Growth
Revenue (TTM)	$51M	$457M
Revenue Growth (YoY)	-64.3%	6.5%
Forward Rev Growth	67.8%	37.6%
Profitability
Gross Margin (TTM)	68.9%	70.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	-2.0%
Net Margin (TTM)	-259.4%	-23.1%
FCF Margin (TTM)	-365.2%	4.6%
Net Income (TTM)	$-132M	$-106M
FCF (TTM)	$-186M	$21M
EPS (TTM)	-$0.85	-$0.82
ROE (TTM)	-18336.0%	-2260.0%
ROA (TTM)	-4290.0%	-1654.0%
ROIC (TTM)	-10716.0%	-2187.0%
Financial Health
Cash	$83M	$46M
Debt	$52M	$12M
Net Cash/Debt	$31M	$34M
Current Ratio (TTM)	1.77x	3.52x
Quick Ratio (TTM)	1.58x	2.66x
Debt/Equity (TTM)	0.85x	0.04x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.44
52W Performance	-39.2%	-68.8%
YTD Performance	-21.9%	-72.2%
% from 52W High	-59.1%	-81.8%
% from 52W Low	9.9%	3.2%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.90x
FCF Yield (TTM)	-112.7%	12.6%
Earnings Yield (TTM)	-80.1%	-63.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	11.1
EV/GP/RG	0.05	0.01
Ticker research	View CHRS research	View ORGO research